Business
Immune drug from Roivant succeeds in new eye disease An immune drug from Roivant could be headed to a new market, after the company reported positive trials in the eye disease non-infectious uveitis.
An immune drug from Roivant could be headed to a new market, after the company reported positive trials in the eye disease non-infectious uveitis.
Dr. Kai NakamuraChief Science CorrespondentPublished Oct 21, 2026 at 10:04 PM EDT · 1 min read
Immune drug from Roivant succeeds in new eye disease An immune drug from Roivant could be headed to a new market, after the company reported positive trials in the eye disease non-infectious uveitis. An immune drug from Roivant could be headed to a new market, after the company reported positive trials in the eye disease non-infectious uveitis.
Continue reading
Latest →Corrections, sourcing and article labels are part of the publication record. See our editorial standards.